Skip to main content

Table 4 Efficacy evaluation of CIGB-300 administration.

From: Safety and preliminary efficacy data of a novel Casein Kinase 2 (CK2) peptide inhibitor administered intralesionally at four dose levels in patients with cervical malignancies

  

Group I

(14 mg)

Group II

(70 mg)

Group III

(245 mg)

Group IV

(490 mg)

TLA

(mean ± SD)

Initial (mm2)

15.7 ± 10.4

7.6 ± 2.7

10.0 ± 7.8

14.5 ± 15.5

 

Final (mm2)

9.9 ± 19.6

2.8 ± 3.9

1.4 ± 14.0

5.0 ± 5.9

 

% Reduction

41.6 ± 41.3

74.6 ± 36.2

95.4 ± 61.2

81.3 ± 19.7

Responders

Colposcopy

6/8 (75.0%)

8/8 (100%)

6/7 (85.7%)

8/8 (100%)

 

Histology

1/8 (12.5%)

3/8 (37.5%)

2/7 (28.6%)

0/8 (0.0%)

 

HPV status

2/6 (33.3%)

4/5 (80.0%)

1/4 (25.0%)

3/6 (50.0%)

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us